Gene editing breakthrough: new therapy aims to stop sickle cell pain crises
NCT ID NCT06565026
First seen Feb 14, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-stage study tests a single injection of CS-101, made from a patient's own gene-edited blood stem cells, for severe sickle cell disease. The goal is to see if it is safe and can reduce or eliminate painful vaso-occlusive crises. The study involves 5 participants aged 12 to 35.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.